FMTX Key Statistics, Chart & Performance
The current stock price of FMTX is 20.01 USD. In the past month the price increased by 0.2%. In the past year, price increased by 10.61%.
FMTX Latest News, Press Relases and Analysis
FMTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.29 | 405.44B | ||
| AMGN | AMGEN INC | 15.29 | 179.97B | ||
| GILD | GILEAD SCIENCES INC | 15.3 | 155.44B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.42 | 108.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.92 | 80.71B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 851.43 | 56.92B | ||
| INSM | INSMED INC | N/A | 43.74B | ||
| NTRA | NATERA INC | N/A | 32.75B | ||
| BIIB | BIOGEN INC | 10.56 | 25.92B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.08 | 21.58B | ||
| INCY | INCYTE CORP | 16.55 | 20.75B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.12B |
Related stock screener links
About FMTX
Company Profile
Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Watertown, Massachusetts and currently employs 189 full-time employees. The company went IPO on 2020-06-16. The firm is focused on the development and commercialization of therapeutics for patients with hematologic diseases and cancers. Its pipeline consists of six product candidates. Its product candidates include etavopivat, FT-7051, Olutasidenib- Acute Myeloid Leukemia IDH1m inhibitor, and Olutasidenib Glioma IDH1m inhibitor. Its lead product candidate, etavopivat, is an oral, once-daily, potentially disease-modifying therapy for the treatment of sickle cell disease (SCD), and other hemoglobinopathies. Its product candidate, FT-7051, is an inhibitor of CREB-binding protein/E1A binding protein p300, or CBP/p300 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Olutasidenib is an oral, selective small molecule investigational agent designed to selectively bind to and inhibit mutated IDH1 enzymes.
Company Info
FORMA THERAPEUTICS HOLDINGS
300 North Beacon Street, Suite 501
Watertown MASSACHUSETTS 02472 US
CEO: Frank D. Lee
Employees: 189
Phone: 16176791970.0
FORMA THERAPEUTICS HOLDINGS / FMTX FAQ
Can you describe the business of FORMA THERAPEUTICS HOLDINGS?
Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Watertown, Massachusetts and currently employs 189 full-time employees. The company went IPO on 2020-06-16. The firm is focused on the development and commercialization of therapeutics for patients with hematologic diseases and cancers. Its pipeline consists of six product candidates. Its product candidates include etavopivat, FT-7051, Olutasidenib- Acute Myeloid Leukemia IDH1m inhibitor, and Olutasidenib Glioma IDH1m inhibitor. Its lead product candidate, etavopivat, is an oral, once-daily, potentially disease-modifying therapy for the treatment of sickle cell disease (SCD), and other hemoglobinopathies. Its product candidate, FT-7051, is an inhibitor of CREB-binding protein/E1A binding protein p300, or CBP/p300 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Olutasidenib is an oral, selective small molecule investigational agent designed to selectively bind to and inhibit mutated IDH1 enzymes.
Can you provide the latest stock price for FORMA THERAPEUTICS HOLDINGS?
The current stock price of FMTX is 20.01 USD. The price increased by 0.15% in the last trading session.
Does FMTX stock pay dividends?
FMTX does not pay a dividend.
How is the ChartMill rating for FORMA THERAPEUTICS HOLDINGS?
FMTX has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is FORMA THERAPEUTICS HOLDINGS (FMTX) stock traded?
FMTX stock is listed on the Nasdaq exchange.
What is the analyst forecast for FMTX stock?
12 analysts have analysed FMTX and the average price target is 21.01 USD. This implies a price increase of 5.01% is expected in the next year compared to the current price of 20.01.
Can you provide the PE ratio for FMTX stock?
FORMA THERAPEUTICS HOLDINGS (FMTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4).
FMTX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to FMTX. When comparing the yearly performance of all stocks, FMTX is one of the better performing stocks in the market, outperforming 99.11% of all stocks.
FMTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to FMTX. No worries on liquidiy or solvency for FMTX as it has an excellent financial health rating, but there are worries on the profitability.
FMTX Financial Highlights
Over the last trailing twelve months FMTX reported a non-GAAP Earnings per Share(EPS) of -4. The EPS decreased by -32.01% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -40.02% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
FMTX Forecast & Estimates
12 analysts have analysed FMTX and the average price target is 21.01 USD. This implies a price increase of 5.01% is expected in the next year compared to the current price of 20.01.